TY - JOUR
T1 - Genetic Spectrum of EYS-associated Retinal Disease in a Large Japanese Cohort
T2 - Identification of Disease-associated Variants with Relatively High Allele Frequency
AU - JEGC study group
AU - Yang, Lizhu
AU - Fujinami, Kaoru
AU - Ueno, Shinji
AU - Kuniyoshi, Kazuki
AU - Hayashi, Takaaki
AU - Kondo, Mineo
AU - Mizota, Atsushi
AU - Naoi, Nobuhisa
AU - Shinoda, Kei
AU - Kameya, Shuhei
AU - Fujinami-Yokokawa, Yu
AU - Liu, Xiao
AU - Arno, Gavin
AU - Pontikos, Nikolas
AU - Kominami, Taro
AU - Terasaki, Hiroko
AU - Sakuramoto, Hiroyuki
AU - Katagiri, Satoshi
AU - Mizobuchi, Kei
AU - Nakamura, Natsuko
AU - Mawatari, Go
AU - Kurihara, Toshihide
AU - Tsubota, Kazuo
AU - Miyake, Yozo
AU - Yoshitake, Kazutoshi
AU - Iwata, Takeshi
AU - Tsunoda, Kazushige
AU - Nishimura, Toshihide
AU - Hayashizaki, Yoshihide
AU - Shimozawa, Nobuhiro
AU - Horiguchi, Masayuki
AU - Yamamoto, Shuichi
AU - Kuze, Manami
AU - Machida, Shigeki
AU - Shimada, Yoshiaki
AU - Nakamura, Makoto
AU - Fujikado, Takashi
AU - Hotta, Yoshihiro
AU - Takahashi, Masayo
AU - Mochizuki, Kiyofumi
AU - Murakami, Akira
AU - Kondo, Hiroyuki
AU - Ishida, Susumu
AU - Nakazawa, Mitsuru
AU - Hatase, Tetsuhisa
AU - Matsunaga, Tatsuo
AU - Maeda, Akiko
AU - Noda, Kosuke
AU - Tanikawa, Atsuhiro
AU - Nakazawa, Toru
N1 - Funding Information:
We thank the patients and their families for participation in this study. We are grateful to Dr. Kazuki Yamazawa and Dr. Satomi Inoue, National Institute of Sensory Organs, National Tokyo Medical Center, Japan for their help in clinical and genetic data analysis. We also thank all the collaborators of Japan Eye Genetics Consortium (URL: http://www.jegc.org/) for data collection. Kaoru Fujinami is supported by grants from Grant-in-Aid for Young Scientists (A) of the Ministry of Education, Culture, Sports, Science and Technology, Japan (16H06269); grants from Grant-in-Aid for Scientists to support international collaborative studies of the Ministry of Education, Culture, Sports, Science and Technology, Japan (16KK01930002); grants from the National Hospital Organization Network Research Fund, Japan (H30-NHO-Sensory Organs-03); grants from FOUNDATION FIGHTING BLINDNESS ALAN LATIES CAREER DEVELOPMENT PROGRAM (CF-CL-0416-0696-UCL); grants from Health Labour Sciences Research Grant, the Ministry of Health, Labour and Welfare, Japan (201711107 A); and grants from the Great Britain Sasakawa Foundation Butterfield Awards, UK. Yu Fujinami-Yokokawa is supported by grants from Grant-in-Aid for Young Scientists of the Ministry of Education, Culture, Sports, Science and Technology, Japan (18K16943). Gavin Arno is supported by a Fight for Sight (UK) early career investigator award, NIHR-BRC at Moorfields Eye Hospital and the UCL Institute of Ophthalmology, NIHR-BRC at Great Ormond Street Hospital and UCL Institute of Child Health, and Great Britain Sasakawa Foundation Butterfield Award, UK. Nikolas Pontikos is funded by the NIHR-BRC at Moorfields Eye Hospital and the UCL Institute of Ophthalmology. Toshihide Kurihara is supported by Tsubota Laboratory, Inc, Fuji Xerox Co., Ltd, Kirin Company, Ltd, Kowa Company, Ltd, Novartis Pharmaceuticals, Santen Pharmaceutical Co. Ltd, and ROHTO Pharmaceutical Co., Ltd. Takeshi Iwata is supported by the Japan Agency for Medical Research and Development (AMED) (18ek0109282h0002). Kazushige Tsunoda is supported by AMED; the Ministry of Health, Labor and Welfare, Japan (18ek0109282h0002); Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Japan (H26-26462674); grants from the National Hospital Organization Network Research Fund, Japan (H30-NHO-Sensory Organs-03) and Novartis Research Grant (2018). Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; the preparation, review, and approval of the manuscript; or the decision to submit the manuscript for publication.
Funding Information:
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor but may receive salary or other support from the institution to support their effort on the project(s). Kaoru Fujinami is a paid consultant of Astellas Pharma Inc, Kubota Pharmaceutical Holdings Co., Ltd, Acucela Inc., Novartis AG., NightstaRx Limited, and Sanofi Genzyme. Kaoru Fujinami reports personal fees from Astellas Pharma Inc, personal fees from Kubota Pharmaceutical Holdings Co., Ltd., personal fees from Acucela Inc., personal fees from Novartis AG., personal fees from SANTEN Company Limited, personal fees from Foundation Fighting Blindness, personal fees from Foundation Fighting Blindness Clinical Research Institute, and personal fees from Japanese Ophthalmology Society, personal fees from Japan Retinitis Pigmentosa Society. The laboratory of Visual Physiology, Division for Vision Research, National Institute of Sensory Organs, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan is supported by grants from Astellas Pharma Inc. (NCT03281005), outside the submitted work. Toshihide Kurihara reports personal fees from Novartis Pharmaceuticals Japan, and Bayer Yakuhin, Ltd., outside the submitted work.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Biallelic variants in the EYS gene are a major cause of autosomal recessive inherited retinal disease (IRD), with a high prevalence in the Asian population. The purpose of this study was to identify pathogenic EYS variants, to determine the clinical/genetic spectrum of EYS-associated retinal disease (EYS-RD), and to discover disease-associated variants with relatively high allele frequency (1%-10%) in a nationwide Japanese cohort. Sixty-six affected subjects from 61 families with biallelic or multiple pathogenic/disease-associated EYS variants were ascertained by whole-exome sequencing. Three phenotype groups were identified in EYS-RD: retinitis pigmentosa (RP; 85.94%), cone-rod dystrophy (CORD; 10.94%), and Leber congenital amaurosis (LCA; 3.12%). Twenty-six pathogenic/disease-associated EYS variants were identified, including seven novel variants. The two most prevalent variants, p.(Gly843Glu) and p.(Thr2465Ser) were found in 26 and twelve families (42.6%, 19.7%), respectively, for which the allele frequency (AF) in the Japanese population was 2.2% and 3.0%, respectively. These results expand the phenotypic and genotypic spectrum of EYS-RD, accounting for a high proportion of EYS-RD both in autosomal recessive RP (23.4%) and autosomal recessive CORD (9.9%) in the Japanese population. The presence of EYS variants with relatively high AF highlights the importance of considering the pathogenicity of non-rare variants in relatively prevalent Mendelian disorders.
AB - Biallelic variants in the EYS gene are a major cause of autosomal recessive inherited retinal disease (IRD), with a high prevalence in the Asian population. The purpose of this study was to identify pathogenic EYS variants, to determine the clinical/genetic spectrum of EYS-associated retinal disease (EYS-RD), and to discover disease-associated variants with relatively high allele frequency (1%-10%) in a nationwide Japanese cohort. Sixty-six affected subjects from 61 families with biallelic or multiple pathogenic/disease-associated EYS variants were ascertained by whole-exome sequencing. Three phenotype groups were identified in EYS-RD: retinitis pigmentosa (RP; 85.94%), cone-rod dystrophy (CORD; 10.94%), and Leber congenital amaurosis (LCA; 3.12%). Twenty-six pathogenic/disease-associated EYS variants were identified, including seven novel variants. The two most prevalent variants, p.(Gly843Glu) and p.(Thr2465Ser) were found in 26 and twelve families (42.6%, 19.7%), respectively, for which the allele frequency (AF) in the Japanese population was 2.2% and 3.0%, respectively. These results expand the phenotypic and genotypic spectrum of EYS-RD, accounting for a high proportion of EYS-RD both in autosomal recessive RP (23.4%) and autosomal recessive CORD (9.9%) in the Japanese population. The presence of EYS variants with relatively high AF highlights the importance of considering the pathogenicity of non-rare variants in relatively prevalent Mendelian disorders.
UR - http://www.scopus.com/inward/record.url?scp=85082561041&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082561041&partnerID=8YFLogxK
U2 - 10.1038/s41598-020-62119-3
DO - 10.1038/s41598-020-62119-3
M3 - Article
C2 - 32218477
AN - SCOPUS:85082561041
SN - 2045-2322
VL - 10
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 5497
ER -